Teneligliptin in Management of Diabetic Kidney Disease: A Review of Place in Therapy

Teneligliptin in Management of Diabetic Kidney Disease: A Review of Place in Therapy

Diabetes is a global health emergency of this century. Diabetic nephropathy is the most common microvascular complication associated with Type 2 Diabetes Mellitus (T2DM). T2DM has been reported as a major etiological factor in almost 45% of patients undergoing dialysis due to kidney failure. Lifes...

Full description

Bibliographic Details
Main Authors:	Mohammed Abubaker, Preetesh Mishra, Onkar C. Swami
Format:	Article
Language:	English
Published:	JCDR Research and Publications Private Limited 2017-01-01
Series:	Journal of Clinical and Diagnostic Research
Subjects:	diabetes mellitus dipeptidyl peptidase-4 inhibitor renal impairment
Online Access:	https://jcdr.net/articles/PDF/9228/25060_CE[Ra1]_F(DK)_PF1(RB_DK)_PFA(DK)_PF2(NE_DK).pdf

Similar Items

Teneligliptin in management of type 2 diabetes mellitus
by: Sharma SK, et al.
Published: (2016-08-01)

Teneligliptin in Early Diabetic Kidney Disease: An Observation in Asian Indian Patients with Type 2 Diabetes Mellitus in Real-Life Scenario
by: Kiran Shah
Published: (2017-06-01)

Phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of teneligliptin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise
by: Linong Ji, et al.
Published: (2021-04-01)

Efficacy and safety of teneligliptin added to metformin in Chinese patients with type 2 diabetes mellitus inadequately controlled with metformin: A phase 3, randomized, double‐blind, placebo‐controlled study
by: Linong Ji, et al.
Published: (2021-04-01)

Linagliptin is associated to increased treatment adherence and satisfaction in elderly outpatients with diabetes and advanced chronic kidney disease
by: Franco Gregorio, et al.
Published: (2016-11-01)

Effects of metformin+sitagliptin versus metformin + glibenclamide combinations on lipid profile, body mass index and kidney function in Iraqi patients with type 2 diabetes mellitus.
by: Hassan Mohammed Abbas Al-Temimi, et al.
Published: (2013-06-01)

Alternate-day dosing of linagliptin in type 2 diabetes patients controlled on once daily dose: A case series
by: Manash P Baruah, et al.
Published: (2016-01-01)

Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
by: Han E, et al.
Published: (2020-11-01)

Multicenter prospective observational study of teneligliptin, a selective dipeptidyl peptidase-4 inhibitor, in patients with poorly controlled type 2 diabetes: Focus on glycemic control, hypotensive effect, and safety Chikushi Anti-Diabetes Mellitus Trial-Teneligliptin (CHAT-T)
by: Yosuke Takamiya, et al.
Published: (2020-04-01)

The persistent inhibitory properties of saxagliptin on renal dipeptidyl peptidase-4: Studies with HK-2 cells in vitro and normal rats in vivo
by: Masako Uchii, et al.
Published: (2017-11-01)

Teneligliptin Co-Infusion Alleviates Morphine Tolerance by Inhibition of Spinal Microglial Cell Activation in Streptozotocin-Induced Diabetic Rats
by: Yaswanth Kuthati, et al.
Published: (2023-07-01)

Efficacy and Safety of Teneligliptin in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Xiaoxuan Li, et al.
Published: (2018-05-01)

Pharmacokinetics of a Fixed-Dose Combination of Teneligliptin Hydrochloride Hydrate and Modified-Release Metformin Under Fasting and Fed Conditions in Healthy Subjects
by: Goak IS, et al.
Published: (2022-12-01)

Time to exacerbation of heart failure is longer in Malaysian population on dipeptidyl peptidase-4 inhibitor
by: J Hasan, et al.
Published: (2017-01-01)

Choosing a Gliptin
by: Vishal Gupta, et al.
Published: (2011-01-01)

Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus
by: Yayoi Nishida, et al.
Published: (2020-04-01)

Comparison of efficacy of add-on therapy of teneligliptin versus pioglitazone among type 2 diabetes mellitus patients ineptly controlled on dual therapy of metformin plus sulfonylurea
by: Vanjari Nikhil Kumar, et al.
Published: (2019-01-01)

The Effect of Dipeptidyl Peptidase-4 Inhibitors on Macrovascular and Microvascular Complications of Diabetes Mellitus: A Systematic Review
by: Olesya M. Taylor, PharmD, BCPS, et al.
Published: (2020-01-01)

Association between Dipeptidyl Peptidase-4 Inhibitor Prescription and Erythropoiesis-Stimulating Agent Hyporesponsiveness in Hemodialysis Patients with Diabetes Mellitus
by: Takeshi Hasegawa, et al.
Published: (2021-04-01)

Possible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy
by: Gagik Radikovich Galstyan, et al.
Published: (2015-12-01)

Dipeptidyl Peptidase-4 Inhibitors and Diabetic Kidney Disease: A Narrative Review
by: Rodrigo Daza-Arnedo, et al.
Published: (2021-11-01)

Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
by: Wang N, et al.
Published: (2019-08-01)

Gemigliptin: Newer promising gliptin for type 2 diabetes mellitus
by: Manish Gutch, et al.
Published: (2017-01-01)

Comparison of canagliflozin and teneligliptin on energy intake and body weight in Japanese patients with Type 2 diabetes: a subanalysis of the CANTABILE study
by: Masahiro Isogawa, et al.
Published: (2024-08-01)

Economic Impact of Combining Metformin with Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients with Renal Impairment in Spanish Patients
by: Antoni Sicras-Mainar, et al.
Published: (2015-02-01)

Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
by: Green J, et al.
Published: (2010-10-01)

Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin
by: Jong Ho Kim, et al.
Published: (2016-04-01)

Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus
by: Kushner P
Published: (2010-04-01)

Factors associated with the glucose‐lowering efficacy of sitagliptin in Japanese patients with type 2 diabetes mellitus: Pooled analysis of Japanese clinical trials
by: Naoko Tajima, et al.
Published: (2020-05-01)

The effect of sitagliptin on hepatic ischemic reperfusion injury in rats
by: Song-Chol Mun, et al.
Published: (2020-01-01)

Pleiotropic effect of teneligliptin versus glimepiride add-on therapy on hs-CRP and cardiorenal parameters in Indian type 2 diabetes patients: An open-labeled randomized controlled trial
by: M Kanimozhi, et al.
Published: (2025-01-01)

Alogliptin prevents diastolic dysfunction and preserves left ventricular mitochondrial function in diabetic rabbits
by: Xiaowei Zhang, et al.
Published: (2018-12-01)

Efficacy and Safety of DPP-4 Inhibitors and Metformin Combinations in Type 2 Diabetes: A Systematic Literature Review and Network Meta-Analysis
by: Chen R, et al.
Published: (2024-06-01)

Evaluation eff ects of IDPP4 therapy diff erent duration on the functional state of α- and β- cells in patients with type 2 diabetes mellitus
by: T. P. Tuchina, et al.
Published: (2022-03-01)

The influence of dipeptidyl peptidase-4 inhibitor on the progression of type B intramural hematoma
by: Qu Chen, et al.
Published: (2022-10-01)

Angioprotektivnoe properties lowering drugs from the group of inhibitors of dipeptidyl peptidase-4
by: E V Oskola, et al.
Published: (2013-09-01)

Ocular cicatricial pemphigoid following Dipeptidyl Peptidase-4 inhibitor use: A case report
by: Akifumi Matsumoto, et al.
Published: (2023-12-01)

Saxagliptin for type 2 diabetes
by: Chacra
Published: (2010-09-01)

Cost-consequence analysis of sitagliptin versus sulfonylureas as add-on therapy for the treatment of diabetic patients in Italy
by: Lorenzoni V, et al.
Published: (2017-11-01)

Effects of metformin and alogliptin on body composition in people with type 2 diabetes
by: Yumie Takeshita, et al.
Published: (2019-05-01)